5th Jun 2024 17:16
LungLife AI, Inc.
("LungLife" or the "Company")
Result of Annual General Meeting
LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that at its Annual General Meeting, held at earlier today, all 10 resolutions put to members were passed on a poll.
Full details of the voting will be available shortly on the Company website here: https://lunglifeai.com/investors/financial-information-documents-presentations/
For further information please contact:
LungLife AI, Inc. | www.lunglifeai.com |
Paul Pagano, CEO | Via Walbrook PR |
David Anderson, CFO |
|
|
|
Investec Bank plc (Nominated Adviser & Broker) | Tel: +44 (0)20 7597 5970 |
Virginia Bull / Cameron MacRitchie / Lydia Zychowska | |
Goodbody (Joint Broker) | Tel: +44 (0) 20 3841 6202 |
Tom Nicholson / Cameron Duncan |
|
|
|
Walbrook PR Limited | Tel: +44 (0)20 7933 8780 or [email protected] |
Alice Woodings / Phillip Marriage | Mob: 07407 804 654 / 07867 984 082 |
About LungLife
LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB® test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com
Our Purpose is to be a driving force in the early detection to lung cancer. Our Vision is to invert the 20:80 ratio such that in years to come at least 80% of lung cancer is detected early.
Related Shares:
Lunglife Ai